{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:08:07Z","timestamp":1779235687294,"version":"3.51.4"},"reference-count":40,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2018,3,2]]},"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hepatic fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) independently predicts mortality. Given liver biopsy\u2019s invasive nature, non-invasive method to assess hepatic steatosis and fibrosis provides NAFLD risk stratification algorithm in clinical practice. NAFLD fibrosis score (NFS) is simple and non-invasive predictive model recommended by American Association for the Study of Liver Disease (AASLD) Guideline to identify patients with NAFLD with fibrosis risk. The aim of this study is to assess long-term outcomes of subjects with significant non-alcoholic steatofibrosis (NASF) as established by ultrasound (US) and NFS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Used National Health and Nutrition Examination Survey (NHANES III) with National Death Index-linked Mortality Files. NAFLD diagnosis established by the presence of moderate to severe hepatic steatosis on US without other causes of chronic liver disease (alcohol consumption &lt;20\u2009gr\/day,hepatitis B surface-antigen negative, anti-hepatitis C virus antibody negative, transferrin saturation &lt;50%). Significant hepatic fibrosis was estimated by high NFS (&gt;0.676) and calculated with previously published formula. Subjects with NAFLD and high NFS have significant NASF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>NHANES III included 20\u2009050 adult participants. 2515 participants complete data and NAFLD with 5.1% (n=129) meeting criteria for significant SF. Subjects with significant SF were older, had higher body mass index, waist circumference and the homeostasis model assessment (HOMA) scores and higher rates of comorbidities (diabetes, congestive heart failure (CHF), stroke; all p&lt;0.001). After median of 207 months of follow-up, overall mortality in NAFLD cohort was 30.0% (n=754). Crude mortality higher in subjects with significant SF (67.4% vs 28.0%, p&lt;0.001). In multivariate survival analysis, predictors of overall mortality included significant SF (adjusted HR (aHR): 1.37; 95% CI 1.07 to 1.76, p=0.01), older age (aHR:1.08; 95% CI 1.07 to 1.09 per year), male gender (aHR:1.44; 95% CI 1.24 to 1.67), black race (aHR:1.24; 95% CI 1.04 to 1.48)), history of hypertension (aHR:1.40; 95% CI 1.20 to 1.64), diabetes (aHR:1.69; 95% CI 1.43 to 2.00), CHF (aHR:1.77; 95% CI 1.38 to 2.261), stroke (aHR:1.84; 95% CI 1.38 to 2.48) and smoking (aHR:1.74; 95% CI 1.47 to 2.07) (all p&lt;0.02). Sensitivity analysis showed that the best association of SF with mortality is higher at NFS threshold of 0.80 (aHR:1.41; 95% CI 1.09 to 1.83, p=0.01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Significant NASF determined non-invasively is an independent predictor of mortality. These data should help clinicians to easily risk-stratify patients with NAFLD for close monitoring and treatment considerations in clinical trial setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2018-000198","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T09:10:11Z","timestamp":1521537011000},"page":"e000198","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)"],"prefix":"10.1136","volume":"5","author":[{"given":"Pegah","family":"Golabi","sequence":"first","affiliation":[{"name":"Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Stepanova","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research in Liver Disease, Columbia, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huong T","family":"Pham","sequence":"additional","affiliation":[{"name":"Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Cable","sequence":"additional","affiliation":[{"name":"Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nila","family":"Rafiq","sequence":"additional","affiliation":[{"name":"Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA"},{"name":"Department of Medicine, Center For Liver Disease, Inova Fairfax Hospital, Falls Church, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley","family":"Bush","sequence":"additional","affiliation":[{"name":"Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor","family":"Gogoll","sequence":"additional","affiliation":[{"name":"Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zobair M","family":"Younossi","sequence":"additional","affiliation":[{"name":"Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA"},{"name":"Department of Medicine, Center For Liver Disease, Inova Fairfax Hospital, Falls Church, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,3,20]]},"reference":[{"key":"2025073013072213000_5.1.e000198.1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cld.2009.02.009","article-title":"Nonalcoholic fatty liver disease: a practical approach to evaluation and management","volume":"13","author":"Rafiq","year":"2009","journal-title":"Clin Liver Dis"},{"key":"2025073013072213000_5.1.e000198.2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the united states and the rest of the world","volume":"20","author":"Sayiner","year":"2016","journal-title":"Clin Liver Dis"},{"key":"2025073013072213000_5.1.e000198.3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/hep.28584","article-title":"Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Lonardo","year":"2016","journal-title":"Hepatology"},{"key":"2025073013072213000_5.1.e000198.4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"2025073013072213000_5.1.e000198.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2016-000106"},{"key":"2025073013072213000_5.1.e000198.6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12955-016-0420-z","article-title":"Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL)","volume":"14","author":"Golabi","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"2025073013072213000_5.1.e000198.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.11.005"},{"key":"2025073013072213000_5.1.e000198.8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/17474124.2016.1099433","article-title":"Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis","volume":"10","author":"Golabi","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2025073013072213000_5.1.e000198.9","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3109\/00365521.2014.934911","article-title":"Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD","volume":"49","author":"\u00d6nnerhag","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"2025073013072213000_5.1.e000198.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70506-8"},{"key":"2025073013072213000_5.1.e000198.11","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2743-5"},{"key":"2025073013072213000_5.1.e000198.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.013"},{"key":"2025073013072213000_5.1.e000198.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.5370"},{"key":"2025073013072213000_5.1.e000198.14","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2446-3"},{"key":"2025073013072213000_5.1.e000198.15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.03.005"},{"key":"2025073013072213000_5.1.e000198.16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-14-166"},{"key":"2025073013072213000_5.1.e000198.17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21327"},{"key":"2025073013072213000_5.1.e000198.18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23521"},{"key":"2025073013072213000_5.1.e000198.19","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.cgh.2017.05.029","article-title":"Long-term outcomes of nonalcoholic fatty liver disease: from nonalcoholic steatohepatitis to nonalcoholic steatofibrosis","volume":"15","author":"Younossi","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025073013072213000_5.1.e000198.20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24268"},{"key":"2025073013072213000_5.1.e000198.21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.084"},{"key":"2025073013072213000_5.1.e000198.22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21496"},{"key":"2025073013072213000_5.1.e000198.23","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1665-2681(19)31004-X","article-title":"Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population","volume":"12","author":"P\u00e9rez-Guti\u00e9rrez","year":"2013","journal-title":"Ann Hepatol"},{"key":"2025073013072213000_5.1.e000198.24","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3748\/wjg.v19.i8.1219","article-title":"NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients","volume":"19","author":"Treeprasertsuk","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2025073013072213000_5.1.e000198.25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26156"},{"key":"2025073013072213000_5.1.e000198.26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25762"},{"key":"2025073013072213000_5.1.e000198.27","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.35354"},{"key":"2025073013072213000_5.1.e000198.28","unstructured":"CDC. U.S. Department of Health and Human Services, National Center for Health Statistics. Third National health and nutrition examination survey, 1998-1994, NHANES III household adult data file. Hyattsville, MD: Center for Disease Control and Prevention, 1996. Public use data file documentation number 77560."},{"key":"2025073013072213000_5.1.e000198.29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"2025073013072213000_5.1.e000198.30","unstructured":"CDC. National Center for Health Statistics. National health and nutrition examination survey: procedure manual, hepatic steatosis. Hyattsville (MD): US Department of Health and Human Services, Centers for Disease Control and Prevention. Center for Disease Control and Prevention, 2010."},{"key":"2025073013072213000_5.1.e000198.31","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.3748\/wjg.v22.i31.7006","article-title":"Metabolic aspects of adult patients with nonalcoholic fatty liver disease","volume":"22","author":"Abenavoli","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2025073013072213000_5.1.e000198.32","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/319215"},{"key":"2025073013072213000_5.1.e000198.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173499","article-title":"Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States","volume":"12","author":"Le","year":"2017","journal-title":"PLoS One"},{"key":"2025073013072213000_5.1.e000198.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.11.034"},{"key":"2025073013072213000_5.1.e000198.35","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.043"},{"key":"2025073013072213000_5.1.e000198.36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27368"},{"key":"2025073013072213000_5.1.e000198.37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep4.1054","article-title":"Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease","volume":"1","author":"Younossi","year":"2017","journal-title":"Hepatol Commun"},{"key":"2025073013072213000_5.1.e000198.38","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","article-title":"Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"145","author":"Angulo","year":"2013","journal-title":"Gastroenterology"},{"key":"2025073013072213000_5.1.e000198.39","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.cgh.2010.04.017","article-title":"Hepatitis C virus infection, age, and Hispanic ethnicity increase mortality from liver cancer in the United States","volume":"8","author":"Younossi","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025073013072213000_5.1.e000198.40","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.09.038"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2018-000198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:07:29Z","timestamp":1753906049000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2018-000198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,3,20]]},"published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1136\/bmjgast-2018-000198"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2018-000198","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}